Phathom Pharmaceuticals Stock Market Value
| PHAT Stock | USD 12.02 0.21 1.72% |
| Symbol | Phathom |
Is there potential for Pharmaceuticals market expansion? Will Phathom introduce new products? Factors like these will boost the valuation of Phathom Pharmaceuticals. Anticipated expansion of Phathom directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Phathom Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.76) | Revenue Per Share | Quarterly Revenue Growth 2.027 | Return On Assets | Return On Equity |
The market value of Phathom Pharmaceuticals is measured differently than its book value, which is the value of Phathom that is recorded on the company's balance sheet. Investors also form their own opinion of Phathom Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phathom Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Phathom Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phathom Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Phathom Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phathom Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Phathom Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Phathom Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Phathom Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Phathom Pharmaceuticals.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Phathom Pharmaceuticals on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Phathom Pharmaceuticals or generate 0.0% return on investment in Phathom Pharmaceuticals over 90 days. Phathom Pharmaceuticals is related to or competes with Nurix Therapeutics, Kodiak Sciences, Xencor, UroGen Pharma, Bicara Therapeutics, Oculis Holding, and BridgeBio Oncology. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing tre... More
Phathom Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Phathom Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Phathom Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 24.16 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 5.99 |
Phathom Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phathom Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Phathom Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Phathom Pharmaceuticals historical prices to predict the future Phathom Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.44) |
Phathom Pharmaceuticals February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 2.82 | |||
| Coefficient Of Variation | (2,939) | |||
| Standard Deviation | 3.8 | |||
| Variance | 14.47 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 24.16 | |||
| Value At Risk | (5.30) | |||
| Potential Upside | 5.99 | |||
| Skewness | (0.21) | |||
| Kurtosis | 2.09 |
Phathom Pharmaceuticals Backtested Returns
Phathom Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0571, which implies the firm had a -0.0571 % return per unit of risk over the last 3 months. Phathom Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Phathom Pharmaceuticals' Risk Adjusted Performance of (0.02), coefficient of variation of (2,939), and Variance of 14.47 to confirm the risk estimate we provide. The company holds a Beta of 0.32, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Phathom Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Phathom Pharmaceuticals is expected to be smaller as well. At this point, Phathom Pharmaceuticals has a negative expected return of -0.22%. Please make sure to check Phathom Pharmaceuticals' jensen alpha, as well as the relationship between the skewness and day median price , to decide if Phathom Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.64 |
Very good reverse predictability
Phathom Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between Phathom Pharmaceuticals time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Phathom Pharmaceuticals price movement. The serial correlation of -0.64 indicates that roughly 64.0% of current Phathom Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.64 | |
| Spearman Rank Test | -0.61 | |
| Residual Average | 0.0 | |
| Price Variance | 2.02 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.